Ovolux Eggshell Membrane Ingredient Earns Multiple Skin Health Claims in Canada

Health Canada has authorized multiple skin health claims for OVOLUX, an eggshell membrane ingredient supplied by Stratum Nutrition.¹ The newly issued product license permits claims covering skin hydration, elasticity, and firmness, along with broader language supporting overall skin health.

For finished product manufacturers, the authorization adds a second major regulatory jurisdiction to the ingredient's portfolio and provides Canadian brand owners with claims language tied to a formal government review rather than a manufacturer's own marketing copy.

"Health Canada's authorization of these claims represents another important milestone for OVOLUX and validates the growing body of science supporting eggshell membrane as a unique beauty-from-within ingredient," commented Arun Nair, Stratum Nutritoin’s chief commercial officer. "As consumer demand for clinically supported skin health solutions continues to grow, OVOLUX offers brands an innovative, sustainable ingredient that addresses key aspects of skin appearance and health."

What Evidence Did Health Canada Require to Authorize These Eggshell Membrane Skin Claims?

Health Canada regulates ingredients like OVOLUX as natural health products through its Natural and Non-prescription Health Products Directorate. Products containing ingredients not already covered by an existing government monograph are reviewed as Class III applications, which require applicants to submit safety and efficacy evidence directly, typically in the form of randomized, double-blind, placebo-controlled human trials conducted at or below the labeled dose.²

The clinical foundation cited for OVOLUX traces to a single-center, randomized, double-blind, placebo-controlled trial published in December 2024 in the Journal of Cosmetics, Dermatological Sciences and Applications.³ The trial enrolled 63 healthy adults aged 35 to 66, randomized to 300 mg per day of unhydrolyzed eggshell membrane or placebo for 12 weeks.

The primary endpoint, skin elasticity in the temporal region of the face, was measured using a Cutometer multi-probe system and showed statistically significant improvement in the treatment group compared with placebo. The study also reported secondary improvements in skin appearance, texture, and hair and fingernail health based on both objective measurements and participant-reported questionnaire scores.

What Does This Authorization Signal for the Beauty-From-Within Category Globally?

OVOLUX has accumulated regulatory standing across more than one jurisdiction, and the Health Canada authorization extends that footprint into the Canadian market specifically, where natural health product claims require a documented government review rather than self-substantiation.

For brand owners formulating ingestible beauty products for sale in Canada, the license provides defined claims language that has already passed regulatory scrutiny, which can shorten internal claims-review processes compared with developing novel language from ingredient-level data alone.

The broader nutricosmetics category has continued to expand based on consumer demand for ingestible alternatives or complements to topical skincare, and ingredient suppliers operating across multiple jurisdictions increasingly use staggered approvals like this one as a basis for global market expansion.

What Limitations Should Manufacturers Consider Before Relying on This Authorization?

It’s important to keep in mind that the Health Canada product license applies specifically to OVOLUX at the studied dose and does not extend automatically to other eggshell membrane ingredients or finished products formulated at different doses without separate regulatory submission.

The underlying clinical evidence is drawn from a single published trial with 63 participants, a modest sample size that, while methodologically sound, has not yet been independently replicated by a separate research group. Additionally, claims authorized under Canada's natural health product framework are not directly transferable to other markets, including the United States, where separate substantiation standards and regulatory pathways apply. Manufacturers should consult the specific authorized claims language and conditions of use issued by Health Canada rather than assuming equivalence with marketing language used in other jurisdictions.

References

1. Health Canada authorizes multiple skin health claims for OVOLUX. Stratum Nutrition June 17, 2026. Accessed June 22, 2026. https://stratumnutrition.com/human/posts/detail/health-canada-authorizes-multiple-skin-health-claims-for-ovolux

2. Pathway for licensing natural health products making modern health claims. Health Canada.. Accessed June 22, 2026. https://www.canada.ca/en/health-canada/services/drugs-health-products/natural-non-prescription/legislation-guidelines/guidance-documents/pathway-licensing-making-modern-health-claims.html

3. Ruff KJ, Dockery N, Aydogan C, Back M. OVOLUX brand eggshell membrane reduces the clinical signs of aging by improving skin, hair & fingernail appearance, texture, and biomechanical properties: a single center, randomized, double blind, placebo controlled clinical trial. J Cosmet Dermatol Sci Appl. 2024;14:306-322. doi:10.4236/jcdsa.2024.144025